Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer
Woman and Man
Between 18 years
and 99 years
Pfizer
Update Il y a 4 ans
Pfizer A6181109 S-TRAC : Essai de phase 3, randomisé en double aveugle, évaluant le sunitinib en traitement adjuvant après chirurgie, chez des patients ayant un cancer du rein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance du sunitinib administré en traitement adjuvant après ablation de la tumeur, chez des patients ayant un cancer du rein. Suite à la ch...
Country
France
organs
Rein
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Pfizer Limited
Update Il y a 4 ans
A Study to Evaluate how Safe and the Body's ability to Tolerate PF-03715455 when Given Twice Daily for 4 Weeks to Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
To determine the effect, at week 4, of orally inhaled PF-03715455 680 micrograms BID on trough FEV1 in subjects with moderate to severe COPD on a stable regimen of short or long acting bronchodilators...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND DMARDS
1. To compare the efficacy of CP-690,550 in doses of 5 mg BID and 10 mg BID versus placebo for the treatment of signs and symptoms of RA in patients with active RA who have had an inadequate response ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Limited. Pfizer Global Research and Development
Update Il y a 4 ans
Full title of the trial: A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain
To evaluate the efficacy of pregabalin compared to placebo in the treatment of post traumatic peripheral neuropathic pain.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
Prevenar Study conducted in Russia
The primary objective is to estimate the incidence of febrile reactions of ≥38 to ≤39°C; >39 to ≤40°C; >40°C occurring within 2 days following vaccination with Prevenar (PCV-7) coadministered with oth...
Country
None
organs
None
Specialty
None
More information
Woman and Man
Between 18 years
and 99 years
Pfizer
Update Il y a 4 ans
B2151007 : Etude de phase 1-2 randomisé, évaluant la dose optimale, la tolérance et l’efficacité du PF-05212384 associé à une chimiothérapie de type FOLFIRI, chez des patients ayant un cancer colorectal métastatique en rechute après une première ligne de traitement à base d’oxaliplatine. [essai suspendu] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer la dose la mieux adaptée du PF-05212384, à administrer en association avec une chimiothérapie de type FOLFIRI, chez des patients ayant un cancer colorectal métast...
Country
France
organs
Côlon ou Rectum (colorectal)
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 4 ans
A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILURE OF ONE PRIOR ANTIANGIOGENIC THERAPY
Primary Objective: To compare the OS of patients with advanced HCC receiving axtitinib + best supportive care (BSC) versus (vs) placebo + BSC following failure of one prior antiangiogenic therapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC
The primary objective of the maraviroc expanded access program is to facilitate access to maraviroc for subjects, who have limited therapeutic options and to collect safety data in a larger and more d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc. 235 East 42nd Street, New York, 10017
Update Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB
Primary Objective: • To demonstrate that the combination of sunitinib plus erlotinib is superior to erlotinib plus placebo in prolonging the overall survival for advanced/metastatic NSCLC patients who...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Primary Objective: Demonstrate superior efficacy of tanezumab 10 mg, 5 mg, and 2.5 mg administered IV every 8 weeks in combination with oral diclofenac SR 75 mg BID versus placebo administered IV ev...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next